keyword
MENU ▼
Read by QxMD icon Read
search

Lamivudine

keyword
https://www.readbyqxmd.com/read/28903510/changes-in-liver-steatosis-after-switching-from-efavirenz-to-raltegravir-among-human-immunodeficiency-virus-infected-patients-with-nonalcoholic-fatty-liver-disease
#1
Juan Macías, María Mancebo, Dolores Merino, Francisco Téllez, M Luisa Montes-Ramírez, Federico Pulido, Antonio Rivero-Juárez, Miguel Raffo, Montserrat Pérez-Pérez, Nicolás Merchante, Manuel Cotarelo, Juan A Pineda
Background: Antiretroviral drugs with a lower potential to induce hepatic steatosis in human immunodeficiency virus (HIV) infection need to be identified. We compared the effect of switching efavirenz (EFV) to raltegravir (RAL) on hepatic steatosis among HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV plus 2 nucleoside analogues. Methods: HIV-infected patients on EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFLD were randomized 1:1 to switch from EFV to RAL (400 mg twice daily), maintaining nucleoside analogues unchanged, or to continue with EFV plus 2 nucleoside analogues...
September 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28901945/correction-dolutegravir-abacavir-lamivudine-versus-current-art-in-virally-suppressed-patients-striiving-a-48-week-randomized-non-inferiority-open-label-phase-iiib-study
#2
Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin A Koteff, Brian Wynne, Judy Hopking, Catherine Granier, Michael Aboud
No abstract text is available yet for this article.
September 13, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28901212/a-retrospective-clinical-audit-of-general-practices-in-australia-to-determine-the-motivation-for-switch-to-dolutegravir-abacavir-lamivudine-and-clinical-outcomes
#3
Pedro E Ferrer, Mark Bloch, Norman Roth, Robert Finlayson, David Baker, Ken Koh, David Orth, Rimgaile Urbaityte, Dannae Brown, Fraser Drummond
The most common reasons for switching HIV-1 therapy in patients with virologic suppression are treatment regimen simplification and resolving tolerability issues. Single-pill regimens that include an integrase inhibitor are recommended options. A retrospective clinical audit was performed to determine the motivations for switching to dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC) at high HIV-caseload general practice clinics in Australia. The most common reasons for switching from a prior suppressive therapy to DTG/ABC/3TC were simplification of regimen, resolving toxicity/intolerance and patient preference (73%, 13% and 12%, respectively)...
January 1, 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/28899424/clade-homogeneity-and-low-rate-of-delta-virus-despite-hyperendemicity-of-hepatitis-b-virus-in-ethiopia
#4
Yeshambel Belyhun, Uwe Gerd Liebert, Melanie Maier
BACKGROUND: Although hepatitis B virus (HBV) is hyperendemic and heterogeneous in its genetic diversity in Ethiopia, little is known about hepatitis D virus (HDV) circulating genotypes and molecular diversity. METHODS: A total of 321 hepatitis B surface antigen (HBsAg) positives (125 HIV co-infected, 102 liver disease patients and 94 blood donors) were screened for anti-HDV antibody. The anti-HDV positive sera were subjected to Real time PCR for HDV-RNA confirmation...
September 12, 2017: Virology Journal
https://www.readbyqxmd.com/read/28893758/antiretroviral-therapy-for-pregnant-women-living-with-hiv-or-hepatitis-b-a-systematic-review-and-meta-analysis
#5
Reed A Siemieniuk, Farid Foroutan, Reza Mirza, Jinell Mah Ming, Paul E Alexander, Arnav Agarwal, Olufunmilayo Lesi, Arnaud Merglen, Yaping Chang, Yuan Zhang, Hassan Mir, Elliot Hepworth, Yung Lee, Dena Zeraatkar, Gordon H Guyatt
OBJECTIVE: To assess the impact of various antiretroviral/antiviral regimens in pregnant women living with HIV or hepatitis B virus (HBV). DESIGN: We performed random effects meta-analysis for HIV-related outcomes and network meta-analysis for HBV outcomes, and used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess quality separately for each outcome. DATA SOURCES: Embase and Medline to February 2017...
September 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28891371/an-observational-retrospective-analysis-evaluating-switching-to-raltegravir-plus-abacavir-lamivudine-in-hiv-1-infected-patients-the-oraswiral-study
#6
Laura Galli, Andrea Poli, Camilla Muccini, Nadia Galizzi, Anna Danise, Vincenzo Spagnuolo, Nicola Gianotti, Elisabetta Carini, Adriano Lazzarin, Antonella Castagna
No abstract text is available yet for this article.
September 11, 2017: Infectious Diseases
https://www.readbyqxmd.com/read/28884132/renal-function-improvement-by-telbivudine-in-liver-transplant-recipients-with-chronic-kidney-disease
#7
Wei-Chen Lee, Tsung-Han Wu, Yu-Chao Wang, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Ching-Song Lee
Chronic renal failure is a frequent complication in liver transplantation. Telbivudine, anti-hepatitis B virus (HBV) nucleoside, can improve renal function. It is interesting if using telbivudine for prophylaxis of HBV recurrence has additional value on renal function improvement. 120 liver transplant recipients with lamivudine prophylaxis for HBV recurrence were 1 : 1 randomized into lamivudine-continuous (n = 60) and telbivudine-replacement (n = 60) groups. Fifty-eight patients in lamivudine-continuous group and 54 in telbivudine-replacement group completed the study...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28882911/predictors-of-hiv-virological-failure-and-drug-resistance-in-chinese-patients-after-48-months-of-antiretroviral-treatment-2008-2012-a-prospective-cohort-study
#8
Wei Kan, Tao Teng, Shujia Liang, Yanling Ma, Heng Tang, Tuerdi Zuohela, Guoqing Sun, Cui He, Kristin M Wall, Vincent C Marconi, Lingjie Liao, Xuebing Leng, Pengtao Liu, Yuhua Ruan, Hui Xing, Yiming Shao
OBJECTIVE: To explore factors associated with HIV virological failure (VF) and HIV drug resistance (HIVDR) among HIV-positive Chinese individuals 4 years after initiating first-line lamivudine-based antiretroviral treatment (ART) in 2008 at five sentinel sites. DESIGN: First-line ART initiators who were previously treatment naïve were selected using consecutive ID numbers from the 2008 National Surveillance Database into a prospective cohort study. Questionnaires and blood samples were collected in 2011 and 2012 to assess the outcomes of interest: VF (defined as viral load ≥1000 copies/mL) and HIVDR (defined as VF with genetic drug-resistant mutations)...
September 7, 2017: BMJ Open
https://www.readbyqxmd.com/read/28877642/to-assess-the-success-of-computerized-order-sets-and-pharmacy-education-modules-in-improving-antiretroviral-prescribing
#9
Dhara Mehta, Bella Kohn, Michael Blumenfeld, Harold W Horowitz
PURPOSE: To assess the success of order set and pharmacist training improvement (OSPTI) in improving prescription of antiretroviral therapy (ART) in a tertiary care, public, teaching hospital. METHODS: In this pre-OSPTI (January 2012 through June 2013) and post-OSPTI study (July 2013 through September 2014), an infectious disease pharmacist reviewed all patients on ART. A review of intervention data in July 2013 led to order-set changes in the hospital's computerized order entry system for frequently intervened on antiretrovirals: ritonavir, tenofovir, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), and lamivudine...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28870666/tenofovir-alafenamide-as-a-rescue-therapy-in-a-cirrhotic-hbv-patient-with-a-hystory-of-fanconi-syndrome-and-multidrug-resistance-a-case-report
#10
Glenda Grossi, Alessandro Loglio, Floriana Facchetti, Marta Borghi, Roberta Soffredini, Enrico Galmozzi, Giovanna Lunghi, Anuj Gaggar, Pietro Lampertico
Tenofovir disoproxil fumarate (TDF) is a recommended first-line therapy for both naïve and experienced chronic hepatitis B (CHB) patients although reduced estimated glomerular filtration rate (eGFR), hypophosphatemia, hyperphosphaturia and Fanconi syndrome have been reported in some patients. Entecavir (ETV) could be considered as a rescue therapy for TDF treated patients developing renal dysfunction, though patients with prior history of treatment with Lamivudine (LAM) can develop ETV resistance strains which can lead to potentially severe hepatitis flares...
September 1, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28870148/accumulation-of-hiv-1-drug-resistance-in-patients-on-a-standard-thymidine-analogue-based-first-line-antiretroviral-therapy-after-virological-failure-implications-for-the-activity-of-next-line-regimens-from-a-longitudinal-study-in-mozambique
#11
Andrea De Luca, Zita Jorge Sidumo, Giacomo Zanelli, Noorjehan Abdul Magid, Richard Luhanga, Davide Brambilla, Giuseppe Liotta, Sandro Mancinelli, Maria Cristina Marazzi, Leonardo Palombi, Susanna Ceffa
BACKGROUND: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of next-line components in patients with virological failure (HIV-1 RNA >1000 copies/mL) after 1 year (t1) of first-line antiretroviral therapy (ART) not switching to second-line drugs for one additional year (t2) in low-middle income countries (LMIC). METHODS AND RESULTS: We selected 48 patients from the DREAM cohort (Maputo, Mozambique); their median pre-ART CD4+ cell count was 165 cells/μl...
September 5, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28867497/bictegravir-emtricitabine-and-tenofovir-alafenamide-versus-dolutegravir-abacavir-and-lamivudine-for-initial-treatment-of-hiv-1-infection-gs-us-380-1489-a-double-blind-multicentre-phase-3-randomised-controlled-non-inferiority-trial
#12
Joel Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczer, Pablo Tebas, Pierre-Marie Girard, Indira Brar, Eric S Daar, David Wohl, Jürgen Rockstroh, Xuelian Wei, Joseph Custodio, Kirsten White, Hal Martin, Andrew Cheng, Erin Quirk
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are recommended components of initial antiretroviral therapy with two nucleoside reverse transcriptase inhibitors. Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug-drug interactions. We aimed to assess the efficacy and safety of bictegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination versus coformulated dolutegravir, abacavir, and lamivudine...
August 31, 2017: Lancet
https://www.readbyqxmd.com/read/28856286/hepatitis-d-b-and-c-virus-hdv-hbv-hcv-coinfection-as-a-diagnostic-problem-and-therapeutic-challenge
#13
Beata Lorenc, Katarzyna Sikorska, Piotr Stalke, Krzysztof Bielawski, Dominik Ziętkowski
Coinfection with hepatitis D virus (HDV) in chronic hepatitis B is associated with more rapid progression to liver cirrhosis. We present two cases of infection with hepatitis D, B and C viruses. Both male patients were primarily diagnosed as infected with hepatitis B virus (HBV) and hepatitis C virus (HCV), HBsAg-positive and anti-HCV-positive. The first patient was treated with interferon, lamivudine and pegylated interferon. A full virological and biochemical response was achieved. The second patient was treated with interferon and ribavirin, lamivudine and twice with pegylated interferon...
March 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28835824/acute-recurrent-lymphocytic-meningitis-in-an-immunocompetent-hiv-positive-african-woman-is-it-a-mollaret-s-meningitis-or-not
#14
Katie Tharshana Yoganathan, Soumeya Cherif, Mariam Rashid, Kathir Yoganathan
We report a case of acute recurrent meningitis in an HIV-positive immunocompetent woman. In this case, a 34-year-old African woman with a known HIV infection presented with symptoms of acute meningitis. She was on combination antiretroviral therapy with abacavir, lamivudine, and nevirapine. Her HIV RNA level was <70 IU/mL, and CD4 counts were 640 cells/mm(3). This indicates that she was not immunocompromised. She was febrile on examination, with marked neck stiffness. Her cerebrospinal fluid revealed raised white cell counts with 100% lymphocytes and mildly raised protein...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28825943/weight-gain-in-persons-with-hiv-switched-from-efavirenz-based-to-integrase-strand-transfer-inhibitor-based-regimens
#15
Jamison Norwood, Megan Turner, Carmen Bofill, Peter Rebeiro, Bryan Shepherd, Sally Bebawy, Todd Hulgan, Stephen Raffanti, David W Haas, Timothy R Sterling, John R Koethe
BACKGROUND: With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART), persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression switched from EFV/TDF/FTC to an INSTI-containing regimen...
August 18, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28806922/hepatitis-b-reactivation-characterized-by-hbsag-negativity-and-anti-hbsag-antibodies-persistence-in-haematopoietic-stem-cell-transplanted-patient-after-lamivudine-withdrawal
#16
C Cerva, G Maffongelli, V Svicher, R Salpini, L Colagrossi, A Battisti, B Mariotti, R Cerretti, L Cudillo, L Sarmati
BACKGROUND: HBV reactivation is associated with high mortality rates in hematopoietic stem cell transplantation (HSCT) and prophylactic lamivudine (LMV) treatment is suggested to prevent this phenomenon. However, the duration of LMV treatment in HSCT patients is not fully defined and the time of immune recovery is considered the best parameter for a drug to be safely interrupted. In patients undergoing allogeneic HSCT, the time of immune recovery is not easy to define and may take years after transplantation and prolonged LMV treatments, which can lead to drug-resistant viral strains...
August 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28797289/insulin-resistance-and-associated-factors-among-hiv-infected-patients-in-sub-saharan-africa-a-cross-sectional-study-from-cameroon
#17
Steve Raoul Ngongang Noumegni, Jobert Richie Nansseu, Vicky Jocelyne Moor Ama, Jean Joel Bigna, Felix Kembe Assah, Magellan Guewo-Fokeng, Steve Leumi, Jean-Claude Katte, Mesmin Dehayem, Andre Pascal Kengne, Eugene Sobngwi
BACKGROUND: Little is known on the magnitude and correlates of insulin resistance in HIV-infected people in Africa. We determined the prevalence of insulin resistance and investigated associated factors in HIV-infected adult Cameroonians. METHODS: We conducted a cross-sectional study at the Yaoundé Central Hospital, Cameroon; during which we enrolled HIV-infected people aged 30 to 74 years with no previous history of cardiovascular disease. An homeostatic model assessment of insulin resistance (HOMA-IR) like index served to assess insulin sensitivity with insulin resistance defined by values of 2...
August 10, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28783807/comparative-safety-of-antiretroviral-treatment-regimens-in-pregnancy
#18
Rebecca Zash, Denise L Jacobson, Modiegi Diseko, Gloria Mayondi, Mompati Mmalane, Max Essex, Chipo Petlo, Shahin Lockman, Joseph Makhema, Roger L Shapiro
Importance: Maternal antiretroviral treatment (ART) started before conception may increase the risk for adverse birth outcomes among women with human immunodeficiency virus (HIV) infection, but whether the risk differs by ART regimen is unknown. Objective: To compare the risk for selected birth outcomes by maternal ART regimen. Design, Setting, and Participants: This observational birth outcomes surveillance study compared all live births and stillbirths with a gestational age of at least 24 weeks in 8 geographically dispersed government hospitals throughout Botswana (approximately 45% of births nationwide)...
August 7, 2017: JAMA Pediatrics
https://www.readbyqxmd.com/read/28770596/high-rates-of-viral-suppression-in-adults-and-children-with-high-cd4-counts-using-a-streamlined-art-delivery-model-in-the-search-trial-in-rural-uganda-and-kenya
#19
Dalsone Kwarisiima, Moses R Kamya, Asiphas Owaraganise, Florence Mwangwa, Dathan M Byonanebye, James Ayieko, Albert Plenty, Doug Black, Tamara D Clark, Bridget Nzarubara, Katherine Snyman, Lillian Brown, Elizabeth Bukusi, Craig R Cohen, Elvin H Geng, Edwin D Charlebois, Theodore D Ruel, Maya L Petersen, Diane Havlir, Vivek Jain
INTRODUCTION: The 2015 WHO recommendation of antiretroviral therapy (ART) for all HIV-positive persons calls for treatment initiation in millions of persons newly eligible with high CD4+ counts. Efficient and effective care models are urgently needed for this population. We evaluated clinical outcomes of asymptomatic HIV-positive adults and children starting ART with high CD4+ counts using a novel streamlined care model in rural Uganda and Kenya. METHODS: In the 16 intervention communities of the HIV test-and-treat Sustainable East Africa Research for Community Health Study (NCT01864603), all HIV-positive individuals irrespective of CD4 were offered ART (efavirenz [EFV]/tenofovir disoproxil fumarate + emtricitabine (FTC) or lamivudine (3TC)...
July 21, 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/28763473/efficacy-and-safety-of-switching-from-branded-to-generic-antiretrovirals-in-virologically-suppressed-hiv-infected-patients
#20
Nicola Gianotti, Andrea Poli, Laura Galli, Michela Franzin, Patrizia Tadini, Nadia Galizzi, Alessia Carbone, Marco Merli, Camilla Muccini, Chiara Oltolini, Andrea Andolina, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Aim of this study was to evaluate the efficacy and the safety of switching from branded to generic antiretrovirals in patients with HIV-RNA <50 copies/mL. METHODS: Matched-cohort study of patients followed at a single clinical center. Since September 2014, all patients with HIV-RNA <50 copies/mL who were receiving branded lamivudine or zidovudine/lamivudine or efavirenz were switched to the generic compound (switchers) and matched, in a ratio 1:1, for age (±5 years), gender, anti-HCV antibodies, nadir and (±50 cells/μL) baseline CD4+ count (±100 cells/μL), duration of antiretroviral therapy (±1 year), with patients with HIV-RNA <50 copies/mL, on treatment with unavailable generic compounds (non-switchers)...
2017: PloS One
keyword
keyword
114587
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"